Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Emblic Myrobalan (Phyllanthus emblica, syn. Emblica officinalis) delivers extraordinary antioxidant and cardioprotective activity through its unique hydrolysable tannins—emblicanin A and B, corilagin, and pedunculagin—alongside exceptionally concentrated vitamin C (191–720 mg/100g) and gallic acid, which collectively scavenge free radicals, chelate pro-oxidant metal ions, and suppress NF-κB-mediated inflammatory cascades. A 2018 systematic review published in the Journal of Cardiovascular and Thoracic Research (PMID 30386531) confirmed Emblica officinalis exerts significant lipid-lowering, anti-atherosclerotic, and cardioprotective effects, validating thousands of years of Ayurvedic clinical application.
Reported Benefits (Provisional)
Origin & History
Emblic Myrobalan (*Phyllanthus emblica*), commonly known as Amla or Indian Gooseberry, is native to tropical and subtropical regions of South and Southeast Asia, particularly India, Pakistan, Sri Lanka, and Bangladesh. This small, round fruit thrives in warm climates with well-drained soils. Revered for its exceptional nutrient density, Amla is a cornerstone in functional nutrition for its potent antioxidant and adaptogenic properties.
Research Narrative (Provisional)
A 2018 systematic review in the Journal of Cardiovascular and Thoracic Research (Hashem-Dabaghian F et al., PMID 30386531) found Emblica officinalis significantly reduces total cholesterol, LDL, and triglycerides while improving HDL profiles, supporting its use in atherosclerosis and cardiovascular disease prevention. A 2021 review in the Journal of Ethnopharmacology (Ahmed S et al., PMID 33465446) validated Triphala—a formulation anchored by Phyllanthus emblica—as a rejuvenating Ayurvedic rasayana, documenting immunomodulatory, anti-inflammatory, and adaptogenic outcomes in contemporary clinical settings. A 2018 review in Chinese Medicine (Tarasiuk A et al., PMID 30034512) highlighted Triphala's efficacy in functional gastrointestinal disorders, attributing its prebiotic and prokinetic effects largely to the tannin-rich emblica component. Additionally, a 2005 study in the International Journal of Food Science and Nutrition (Bajpai M et al., PMID 16096138) quantified emblic myrobalan as among the highest phenolic-content medicinal plants tested, with antioxidant activity surpassing many common dietary fruits.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Vitamins: Exceptionally high in Vitamin C (ascorbic acid), up to 600 mg per 100g. - Polyphenols: Ellagitannins, gallic acid, quercetin, kaempferol. - Minerals: Calcium, phosphorus, iron, chromium. - Fiber: Soluble dietary fiber.
Reported Mechanism (Provisional)
Emblic Myrobalan's hydrolysable tannins—emblicanin A, emblicanin B, corilagin, punigluconin, and pedunculagin—exert potent free radical scavenging by donating hydrogen atoms to neutralize reactive oxygen species (ROS), while their polyhydroxyl structures enable chelation of ferrous and cupric ions, interrupting Fenton-type oxidative chain reactions at the molecular level. Corilagin, specifically highlighted in a 2023 review in Mini Reviews in Medicinal Chemistry (Wang X et al., PMID 36635908), inhibits NF-κB and MAPK signaling pathways, downregulating pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, while also demonstrating antiviral interference with viral protease and replication machinery. Gallic acid and ellagic acid upregulate endogenous antioxidant enzymes—superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)—by activating the Nrf2/ARE transcriptional pathway, amplifying cellular cytoprotection beyond direct scavenging. The fruit's soluble fiber and tannin content further modulates gut microbiota composition, reducing intestinal permeability and systemic lipopolysaccharide (LPS)-driven inflammation through Toll-like receptor 4 (TLR4) pathway suppression.
Clinical Narrative (Provisional)
High-quality human clinical trials confirm vasodilatory effects, myocardial antioxidant properties, and anti-platelet aggregation activity. Preclinical studies demonstrate cytotoxic activity with IC50 values of 52.2 μg/mL against cholangiocarcinoma cells and 82-97% inhibition of various cancer cell lines including lung and neuroblastoma. Antibacterial studies show 17-25 mm zones of inhibition against pathogenic bacteria including Shigella dysenteriae and Staphylococcus aureus. While traditional use is extensive, more large-scale human trials are needed to establish optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.